BORRELIA BURGDORFERI IGG WESTERN BLOT TEST SYSTEM

K991180 · Zeus Scientific, Inc. · LSR · Sep 3, 1999 · Microbiology

Device Facts

• Record ID: K991180
• Device Name: BORRELIA BURGDORFERI IGG WESTERN BLOT TEST SYSTEM
• Applicant: Zeus Scientific, Inc.
• Product Code: LSR · Microbiology
• Decision Date: Sep 3, 1999
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.3830
• Device Class: Class 2

Intended Use

The Zeus Scientific, Inc., B. burgdorferi Western Blot Test System is designed for the qualitative detection of IgG class antibodies to specific proteins associated with B. burgdorferi, the causative agent of Lyme Disease. The test system is intended to be used for testing human serum samples which have been found to be positive or equivocal by an EIA or IFA screening procedure. The test is therefore intended to provide supportive evidence of infection of Borrelia burgdorferi.

Device Story

The Borrelia burgdorferi IgG Western Blot Test System is an in vitro diagnostic assay used in clinical laboratories. It processes human serum samples that have already screened positive or equivocal via EIA or IFA. The device utilizes Western Blot technology to detect IgG class antibodies specific to B. burgdorferi proteins. The test provides qualitative results that serve as supportive evidence for Lyme disease infection. Healthcare providers use these results to confirm clinical suspicion of infection. The device is intended for prescription use only.

Clinical Evidence

No clinical data provided in the document.

Technological Characteristics

In vitro diagnostic Western Blot test system for qualitative detection of IgG antibodies. Utilizes specific protein antigens associated with B. burgdorferi. Manual or semi-automated laboratory test format.

Indications for Use

Indicated for qualitative detection of IgG antibodies to B. burgdorferi in human serum samples previously testing positive or equivocal by EIA or IFA screening. Used as supportive evidence for Lyme disease infection.

Regulatory Classification

Identification

Treponema pallidum treponemal test reagents are devices that consist of the antigens, antisera and all control reagents (standardized reagents with which test results are compared) which are derived from treponemal sources and that are used in the fluorescent treponemal antibody absorption test (FTA-ABS), the Treponema pallidum immobilization test (T.P.I.), and other treponemal tests used to identify antibodies to Treponema pallidum directly from infecting treponemal organisms in serum. The identification aids in the diagnosis of syphilis caused by bacteria belonging to the genus Treponema and provides epidemiological information on syphilis.

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of three human profiles facing right, stacked on top of each other. The profiles are simple and abstract, with flowing lines. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the image.

SEP 3 1999 Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Mr. Mark J. Kopnitsky Vice President of Research & Development Zeus Scientific, Inc. 200 Evans Way Branchburg, New Jersey 08876

Re: K991180

> Trade Name: Borrelia burgdorferi IgG Western Blot Test System Regulatory Class: II Product Code: LSR Dated: June 25, 1999 Received: June 29, 1999

Dear Mr. Kopnitsky:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{1}------------------------------------------------

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at [phone].

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number [phone] or at [phone] or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"

Sincerely yours,

Steven Butman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Page 1 of 1

510(k) Number (if known):

Device Name: Borrelia burgdorferi IgG Western Blot Test System

Indications for Use:

Borrelia burgdorferi IgG Western Blot Test System; 3Z71001G

The Zeus Scientific, Inc., B. burgdorferi Western Blot Test System is designed for the qualitative detection of IgG class antibodies to specific proteins associated with B. burgdorferi, the causative agent of Lyme Disease. The test system is intended to be used for testing human serum samples which have been found to be positive or equivocal by an EIA or IFA screening procedure. The test is therefore intended to provide supportive evidence of infection of Borrelia burgdorferi.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Woody Dubois

(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K99/180

| Prescription Use | X |
|----------------------|---|
| (Per 21 CFR 801,109) | |

OR

Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________

(Optional Format 1-2-96)